Fox Chase Cancer Center Physician Researcher Receives Young Investigator Award from World's Leading Professional Society for Oncologists
PHILADELPHIA (June 2, 2004) -- The ASCO Foundation of the American Society of Clinical Oncology (ASCO) has selected Hossein Borghaei, D.O., assistant member in the Department of Medical Oncology at Fox Chase Cancer Center, to receive a 2004 Young Investigator Award. The award was presented at the Society's 40th Annual Meeting in New Orleans, Louisiana.
Young Investigator Awards are presented to physicians during their transition from a fellowship program to a faculty appointment, and to those who intend to pursue investigative careers in clinical oncology. Each of the 41 recipients selected this year will receive a one-year grant of $35,000 to begin his or her investigative studies.
Borghaei has completed his fellowship at Fox Chase as chief fellow. His research interest involves the use of monoclonal antibodies to treat cancer. Antibodies are tiny proteins that fight off foreign proteins in the body such as a cold, and in some cases, cancer. In cancer therapy, monoclonal antibodies are engineered to seek and destroy specific proteins found on the surface of cancer cells, thus killing the cancer. Each cancer cell can have a different set of proteins on its surface.
In addition to his laboratory research, Borghaei specializes in the treatment of hematologic malignancies and lung cancer.
Borghaei received his B.S. in biology from St. Joseph's University, Philadelphia, Pa., his M.S. in microbiology from Temple University and his D.O. from Philadelphia College of Osteopathic Medicine. He is a member of the American Society of Clinical Oncology and the American Osteopathic Association.
The ASCO Foundation grants the Young Investigator Awards based on the outstanding quality of the recipients' clinical oncology research proposals as well as their experience. Other factors in the selection process include achievements in previous scientific training, potential for independent investigation, and proven commitment to careers in clinical research.
"ASCO's continued commitment to support clinical investigators at a critical stage in their early careers will expand the cadre of expert clinical oncology researchers who are developing promising research initiatives in all areas of cancer," said Elizabeth A. Eisenhauer, MD, chair of ASCO Foundation's grant selection committee.
Borghaei's award is sponsored by Centocor.
The American Society of Clinical Oncology (ASCO) is the world's leading professional society of multidisciplinary physicians who treat people with cancer. ASCO's more than 20,000 members from the U.S. and abroad set the standard for patient care worldwide and lead the fight for more effective cancer treatments, increased funding for clinical and translational research, and, ultimately, cures for the many different types of cancer that strike an estimated 10 million people worldwide each year.
The ASCO Foundation is a charitable organization dedicated to supporting ASCO's education and research mission worldwide by funding initiatives in high-quality cancer care and prevention, career development, and patient education. The ASCO Foundation Grants Program selects leading young clinical oncologists across a broad range of specialties from around the world.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.